Literature DB >> 16825927

Extraintestinal manifestations of inflammatory bowel diseases.

Sripathi R Kethu1.   

Abstract

Inflammatory bowel diseases are associated with extraintestinal manifestations involving almost every organ system in the body. They occur in approximately 20% to 40% of patients with inflammatory bowel diseases. Immune-related and genetic mechanisms play an important role in the pathogenesis of these complications. Peripheral arthritis, erythema nodosum, and episcleritis respond to the treatment of the underlying intestinal inflammation, whereas axial arthropathy, pyoderma gangrenosum, and uveitis do not. Immunomodulator therapy, particularly with biologic agents has been shown to be effective in treating some of the extraintestinal manifestations. Early recognition and treatment are crucial in preventing major morbidity.

Entities:  

Mesh:

Year:  2006        PMID: 16825927     DOI: 10.1097/00004836-200607000-00003

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  12 in total

1.  Pyostomatitis vegetans: cellular immune profile and expression of IL-6, IL-8 and TNF-alpha.

Authors:  Giuseppe Ficarra; Gianna Baroni; Daniela Massi
Journal:  Head Neck Pathol       Date:  2009-11-14

Review 2.  Crohn's disease and skin.

Authors:  A G Gravina; A Federico; E Ruocco; A Lo Schiavo; F Romano; A Miranda; D Sgambato; M Dallio; V Ruocco; C Loguercio; M Romano
Journal:  United European Gastroenterol J       Date:  2015-08-21       Impact factor: 4.623

3.  Assessment of Hearing Function in Children with Inflammatory Bowel Disease.

Authors:  Esra Polat; Zehra Çınar; Gonca Keskindemirci; Özgür Yiğit; Günsel Kutluk; Muhammet Türe; Tuğberk Akça; Esat Alkaya
Journal:  J Int Adv Otol       Date:  2020-12       Impact factor: 1.017

Review 4.  Clinical immunology review series: an approach to the patient with recurrent superficial abscesses.

Authors:  S L Johnston
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

5.  Decreased total antioxidant capacity in plasma, but not tissue, in experimental colitis.

Authors:  José Wander Breganó; Jane Bandeira Dichi; Décio Sabbatini Barbosa; Mirian Zebian El Kadri; Tiemi Matsuo; Maria Aparecida Rodrigues; Rubens Cecchini; Isaias Dichi
Journal:  Dig Dis Sci       Date:  2008-08-22       Impact factor: 3.199

6.  Skin manifestations of inflammatory bowel disease.

Authors:  Brian L Huang; Stephanie Chandra; David Quan Shih
Journal:  Front Physiol       Date:  2012-02-06       Impact factor: 4.566

Review 7.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012

8.  Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.

Authors:  Benjamin Siemanowski; Miguel Regueiro
Journal:  Curr Treat Options Gastroenterol       Date:  2007-06

9.  Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines.

Authors:  Amarjargal Dashdorj; K R Jyothi; Sangbin Lim; Ara Jo; Minh Nam Nguyen; Joohun Ha; Kyung-Sik Yoon; Hyo Jong Kim; Jae-Hoon Park; Michael P Murphy; Sung Soo Kim
Journal:  BMC Med       Date:  2013-08-06       Impact factor: 8.775

10.  Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.

Authors:  Nina Roth; Luc Biedermann; Nicolas Fournier; Matthias Butter; Stephan R Vavricka; Alexander A Navarini; Gerhard Rogler; Michael Scharl
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.